StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. OCX has been the topic of a ...

Lake Street 分析师认为，OncoCyte 目前的市场估值并未反映公司的潜力，表明当前股价为长期投资者提供了一个有吸引力的入场点。该公司启动覆盖并给予"买入"评级和5美元的目标价是基于这些因素，表明对 OncoCyte 未来表现的信心。随着公司下一次财报将于4月4日发布，投资者可以通过 InvestingPro ...

EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest ...

Investing.com — 周二，Needham重申了对OncoCyte Corp (NASDAQ: OCX )的买入评级，目标价维持在4.25美元不变，较当前3.33美元的价格有28%的上涨空间。尽管近期波动，该股今年迄今表现强劲，上涨近40%。该公司分析师强调了与Bio-Rad成功持续联合营销GraftAssure RUO以及OncoCyte与移植中心的持续合作关系。

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Fintel reports that on March 28, 2025, Lake Street initiated coverage of OncoCyte (NasdaqCM:OCX) with a Buy recommendation.

Discover OncoCyte's Q4 2024 progress with its cutting-edge kidney transplant test. Insights on FDA ambitions, market strategies & financial runway.

Stephens & Co.：重申OncoCyte(OCX.US)评级，由持股观望调整至持股观望评级, 目标价由4.00美元调整至4.00美元。 OncoCyte（OCX.US）公司简介：OncoCyte Corp 专注于 ...

OncoCyte Corp (OCX) advances with new product launches and strategic alliances, while navigating regulatory hurdles and competitive pressures.

Oncocyte is at a pivotal stage in commercializing what we expect to be an industry-transforming organ transplant rejection monitoring test. We aim to deliver proven, more affordable, faster tests ...

Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...

As of March 19, 2025, the average one-year price target for OncoCyte is 4.12 GBX/share. The forecasts range from a low of 3.96 GBX to a high of 4.37 GBX. The average price target represents an ...